Skip to Main Content

Advertisement

Skip Nav Destination

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Blood (2018) 132 (Supplement 1): 287.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement